Skip to main content
SpringerLink
Log in

Antagonist of the Type-1 ANG II receptor prevents against LPS-induced septic shock in rats

  • Experimental
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Purpose

Type 1 angiotensin II (AT1) receptor antagonists have anti-inflammatory effects in vitro and in patients. The purpose of this study was to investigate whether losartan (LOS), an AT1 receptor antagonist, reduces lung damage by inhibiting the induction of high mobility group box 1 (HMGB1) protein and cytokines by lipopolysaccharide (LPS; serotype: O127:B8) in a rat model.

Methods

We used male Wistar rats. Control group rats received a 0.9% NaCl solution. The LOS + LPS group rats received LOS (50 mg kg−1) before LPS (7.5 mg kg−1) administration. LPS group rats received injection of LPS (7.5 mg kg−1).

Measurements and results

We performed immunohistochemistry, ELISA, and western blot analysis to examine the suppressive effects of LOS on LPS-induced cytokine induction. Plasma concentrations of cytokines (IL-6 and TNF-α) and HMGB1 (p < 0.05) were markedly reduced in the LOS + LPS group compared to the LPS group. LOS also inhibited the LPS-mediated decrease in angiotensin-converting enzyme 2 (ACE2) activity (p < 0.05). Immunohistochemical analysis revealed positive staining for ACE2 in lungs from both control and LOS + LPS groups. The intensity and degree of ACE2 labeling in lung tissue sections from the LPS group were markedly reduced compared to the control and LOS + LPS groups (p < 0.05). Additionally, RAW264.7 murine macrophages were stimulated with LPS, with or without simultaneous LOS treatment, resulting in inhibition of IκB phosphorylation.

Conclusions

Treatment with LOS improved lung injury in an endotoxin shock model system by an anti-inflammatory action that inhibits reduction of ACE2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Heron M (2007) Deaths: leading causes for 2004. Natl Vital Stat Rep 56:1–95

    PubMed  Google Scholar 

  2. Martin GS, Mannino DM, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554

    Article  PubMed  Google Scholar 

  3. Wyncoll LA, Evans TW (1999) Acute respiratory distress syndrome. Lancet 354:497–501

    Article  PubMed  CAS  Google Scholar 

  4. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115–1124

    Article  PubMed  CAS  Google Scholar 

  5. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934–941

    Article  PubMed  CAS  Google Scholar 

  6. Riedemann NC, Ward PA (2003) The enigma of sepsis. J Clin Invest 112:460–467

    PubMed  CAS  Google Scholar 

  7. Wang H, Yang H, Tracey KJ (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768–1773

    PubMed  CAS  Google Scholar 

  8. Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19:5237–5246

    PubMed  CAS  Google Scholar 

  9. Wang H, Yang H, Zhang M (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251

    Article  PubMed  CAS  Google Scholar 

  10. Wang H, Vishnubhakat JM, Tracey KJ (1999) Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389–392

    PubMed  CAS  Google Scholar 

  11. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321–329

    Article  PubMed  CAS  Google Scholar 

  12. Krämer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Böger RH, Forssmann WG, Drexler H, Schieffer B (2002) Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 90:770–776

    Article  PubMed  Google Scholar 

  13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869 RENAAL Study Investigators

    Article  PubMed  CAS  Google Scholar 

  14. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776 CHARM Investigators, Committees

    Article  PubMed  CAS  Google Scholar 

  15. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003 LIFE Study Group

    Article  PubMed  Google Scholar 

  16. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:112–116

    Article  PubMed  CAS  Google Scholar 

  17. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111:2605–2610

    Article  PubMed  CAS  Google Scholar 

  18. Murakami K, McGuire R, Cox RA (2002) Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236–241

    Article  PubMed  Google Scholar 

  19. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T (2008) High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 34:361–367

    Article  PubMed  CAS  Google Scholar 

  20. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9

    PubMed  CAS  Google Scholar 

  21. Harmer D, Gilbert M, Borman R, Clark KL (2002) Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532:107–110

    Article  PubMed  CAS  Google Scholar 

  22. Danilczyk U, Penninger JM (2006) Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98:463–471

    Article  PubMed  CAS  Google Scholar 

  23. Parsons PE, Moore FA, Moore EE, Iklé DN, Henson PM, Worthen GS (1992) Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. Am Rev Respir Dis 146:694–700

    PubMed  CAS  Google Scholar 

  24. Abraham E, Jesmok G, Tuder R, Allbee J, Chang YH (1995) Contribution of tumor necrosis factor-alpha to pulmonary cytokine expression and lung injury after hemorrhage and resuscitation. Crit Care Med 23:1319–1326

    Article  PubMed  CAS  Google Scholar 

  25. Parsey MV, Tuder RM, Abraham E (1998) Neutrophils are major contributors to intraparenchymal lung IL-1 beta expression after hemorrhage and endotoxemia. J Immunol 160:1007–1013

    PubMed  CAS  Google Scholar 

  26. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA (2002) Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463–467

    Article  PubMed  Google Scholar 

  27. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310–1316

    Article  PubMed  Google Scholar 

  28. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ (2000) HMGB1 as a mediator of acute lung inflammation. J Immunol 165:2950–2954

    PubMed  CAS  Google Scholar 

  29. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734

    Article  PubMed  CAS  Google Scholar 

  30. Liu SF, Malik AB (2006) NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290:622–645

    Article  Google Scholar 

  31. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179:33–40

    Article  PubMed  CAS  Google Scholar 

  32. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, Park DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR (2001) Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 164:1896–1903

    PubMed  CAS  Google Scholar 

  33. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870–C879

    PubMed  CAS  Google Scholar 

  34. Liu SF, Malik AB (2006) NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290:L622–L645

    Article  PubMed  CAS  Google Scholar 

  35. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85–94

    Article  PubMed  CAS  Google Scholar 

  36. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG (2005) Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315:1188–1195

    Article  PubMed  CAS  Google Scholar 

  37. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868–31874

    Article  PubMed  CAS  Google Scholar 

  38. Bonizzi G, Karin M (2005) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288

    Article  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Dr. Tomohisa Uchida for providing helpful advice and for scoring lung injuries.

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, 1-1 Idaigaoka-Hasamamachi, Yufu, Oita, 879-5593, Japan

    Satoshi Hagiwara, Hideo Iwasaka, Seigo Hidaka, Akira Hasegawa, Hironori Koga & Takayuki Noguchi

Authors
  1. Satoshi Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideo Iwasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seigo Hidaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hironori Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takayuki Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Hagiwara.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material (DOC 2294 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagiwara, S., Iwasaka, H., Hidaka, S. et al. Antagonist of the Type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med 35, 1471–1478 (2009). https://doi.org/10.1007/s00134-009-1545-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-009-1545-x

Keywords

Search

Navigation